Dr. Peter Block interviews Dr. Michael Gibson on the results PIONEER AF-PCI trial which explored two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist strategy in subjects with atrial fibrillation who undergo PCI.

Keywords: AHA Annual Scientific Sessions, AHA16, Administration, Oral, Acute Coronary Syndrome, Anticoagulants, Atrial Fibrillation, Percutaneous Coronary Intervention, Research Design, Vitamin K

< Back to Listings